Cannabinoid influence on cytokine profile in multiple sclerosis.

Author(s): Katona S, Kaminski E, Sanders H, Zajicek J

Affiliation(s): Department of Immunology, Derriford Hospital, Plymouth PL6 8DH, UK.

Publication date & source: 2005-06, Clin Exp Immunol., 140(3):580-5.

Publication type: Clinical Trial; Randomized Controlled Trial

Cannabinoids have been suggested as possessing immunomodulatory properties, and cannabinoid receptors are present on leucocytes. Clinically, there is some evidence that cannabinoids may be therapeutically useful in treating multiple sclerosis, which is generally believed to be an autoimmune condition. This paper reports data derived from the Cannabinoids in MS (CAMS) study, which was the largest randomized controlled trial yet conducted to evaluate the therapeutic efficacy of cannabinoids. We found no evidence for cannabinoid influence on serum levels of interferon (IFN)-gamma, interleukin (IL)-10, IL-12 or C-reactive protein as measured using enzyme-linked immunosorbent assay (ELISA), in comparison to control values. Mitogenic stimulation experiments also failed to demonstrate any significant reduction in percentage of CD3+, IFN-gamma producing cells after exposure to cannabinoids in vivo, although numbers were small. Further work is needed to establish the functional significance of cannabinoid receptors on immune cells.